QT Imaging Clears First FDA Inspection with Zero Form 483 Findings
QTI•QT Imaging successfully completed its first routine FDA inspection with zero Form 483 observations, validating its Quality Management System. The inspector praised the organization’s operational discipline and responsiveness, supporting the company’s scaling of manufacturing and global commercialization efforts.
1. FDA Inspection Results
QT Imaging completed its first FDA routine inspection without receiving any Form 483 observations, marking a key regulatory milestone for the company’s device manufacturing operations.
2. QMS Validation and Feedback
The inspection reviewed the company’s Quality Management System and related operational processes, with the FDA inspector offering positive feedback on system organization and the team’s responsiveness throughout the audit.
3. Operational and Commercial Impact
This outcome strengthens confidence in QT Imaging’s ability to scale production, expand global commercialization of its low-frequency body imaging systems, and maintain rigorous quality standards for a growing customer base.
